1. Home
  2. EEX vs NUVB Comparison

EEX vs NUVB Comparison

Compare EEX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EEX
  • NUVB
  • Stock Information
  • Founded
  • EEX 2013
  • NUVB 2018
  • Country
  • EEX United States
  • NUVB United States
  • Employees
  • EEX N/A
  • NUVB N/A
  • Industry
  • EEX Advertising
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • EEX Consumer Discretionary
  • NUVB Health Care
  • Exchange
  • EEX Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • EEX 1.0B
  • NUVB 837.0M
  • IPO Year
  • EEX 2017
  • NUVB N/A
  • Fundamental
  • Price
  • EEX $4.96
  • NUVB $3.17
  • Analyst Decision
  • EEX Strong Buy
  • NUVB Strong Buy
  • Analyst Count
  • EEX 2
  • NUVB 6
  • Target Price
  • EEX $7.95
  • NUVB $8.17
  • AVG Volume (30 Days)
  • EEX 34.7K
  • NUVB 6.5M
  • Earning Date
  • EEX 10-29-2025
  • NUVB 11-05-2025
  • Dividend Yield
  • EEX 1.22%
  • NUVB N/A
  • EPS Growth
  • EEX N/A
  • NUVB N/A
  • EPS
  • EEX 0.04
  • NUVB N/A
  • Revenue
  • EEX $432,600,000.00
  • NUVB $14,355,000.00
  • Revenue This Year
  • EEX $15.99
  • NUVB $332.80
  • Revenue Next Year
  • EEX $7.56
  • NUVB $360.12
  • P/E Ratio
  • EEX $134.21
  • NUVB N/A
  • Revenue Growth
  • EEX 9.96
  • NUVB 900.35
  • 52 Week Low
  • EEX $3.22
  • NUVB $1.54
  • 52 Week High
  • EEX $6.45
  • NUVB $4.09
  • Technical
  • Relative Strength Index (RSI)
  • EEX 50.11
  • NUVB 54.68
  • Support Level
  • EEX $4.80
  • NUVB $3.20
  • Resistance Level
  • EEX $5.45
  • NUVB $3.44
  • Average True Range (ATR)
  • EEX 0.22
  • NUVB 0.26
  • MACD
  • EEX -0.02
  • NUVB -0.00
  • Stochastic Oscillator
  • EEX 37.69
  • NUVB 24.70

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: